• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

估算连续有界结局数据的重复测量建模的变换。

Estimating transformations for repeated measures modeling of continuous bounded outcome data.

机构信息

Ann Arbor Pharmacometrics Group (A2PG), 110 E Miller, Garden Suite, Ann Arbor, MI 48104, USA.

出版信息

Stat Med. 2011 Apr 30;30(9):935-49. doi: 10.1002/sim.4155. Epub 2011 Jan 13.

DOI:10.1002/sim.4155
PMID:21472758
Abstract

Continuous bounded outcome data are unlikely to meet the usual assumptions for mixed-effects models of normally distributed and independent subject-specific and residual random effects. Additionally, overly complicated model structures might be necessary to account adequately for non-drug (time-dependent) and drug treatment effects. A transformation strategy with a likelihood component for censoring is developed to promote the simplicity of model structures and to improve the plausibility of assumptions on the random effects. The approach is motivated by Health Assessment Questionnaire Disability Index (HAQ-DI) data from a study in subjects with rheumatoid arthritis and is evaluated using a simulation study.

摘要

连续有界的结果数据不太可能满足通常的假设,即混合效应模型适用于正态分布和独立的个体特定随机效应和残差随机效应。此外,可能需要过于复杂的模型结构来充分说明非药物(时间相关)和药物治疗效果。开发了一种带有删失似然成分的转换策略,以促进模型结构的简单性,并提高对随机效应的假设的合理性。该方法的动机是来自类风湿关节炎患者研究的健康评估问卷残疾指数 (HAQ-DI) 数据,并使用模拟研究进行评估。

相似文献

1
Estimating transformations for repeated measures modeling of continuous bounded outcome data.估算连续有界结局数据的重复测量建模的变换。
Stat Med. 2011 Apr 30;30(9):935-49. doi: 10.1002/sim.4155. Epub 2011 Jan 13.
2
Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.患者摘要:托法替布用于治疗类风湿关节炎。
Ann Intern Med. 2013 Aug 20;159(4):I-26. doi: 10.7326/0003-4819-159-4-201308200-00002.
3
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.CP-690550,一种JAK3抑制剂,作为免疫抑制剂用于治疗类风湿性关节炎、移植排斥反应、银屑病及其他免疫介导的疾病。
Curr Opin Investig Drugs. 2009 May;10(5):491-504.
4
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.在类风湿关节炎中进行 JAK 抑制剂的体外和体内分析。
Ann Rheum Dis. 2012 Apr;71 Suppl 2:i70-4. doi: 10.1136/annrheumdis-2011-200595.
5
The logistic transform for bounded outcome scores.有界结果分数的逻辑斯蒂变换。
Biostatistics. 2007 Jan;8(1):72-85. doi: 10.1093/biostatistics/kxj034. Epub 2006 Apr 5.
6
Tofacitinib for the treatment of rheumatoid arthritis.托法替布治疗类风湿关节炎。
Expert Rev Clin Immunol. 2012 May;8(4):319-31. doi: 10.1586/eci.12.19.
7
Tofacitinib (Xeljanz) for rheumatoid arthritis.托法替布(尚杰)用于治疗类风湿关节炎。
Med Lett Drugs Ther. 2013 Jan 7;55(1407):1-3.
8
The use of bootstrap methods for analysing Health-Related Quality of Life outcomes (particularly the SF-36).使用自助法分析健康相关生活质量结果(特别是SF-36量表)。
Health Qual Life Outcomes. 2004 Dec 9;2:70. doi: 10.1186/1477-7525-2-70.
9
Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.类风湿关节炎临床试验结果测量的比较:一项模拟研究。
Arthritis Rheum. 2003 Nov;48(11):3031-8. doi: 10.1002/art.11293.
10
Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.激酶抑制剂作为口服类风湿性关节炎药物受到关注。
Nat Rev Drug Discov. 2010 Apr;9(4):257-8. doi: 10.1038/nrd3155.

引用本文的文献

1
Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.在单独给予ervogastat以及与clesacostat联合给药的非酒精性脂肪性肝病患者群体中,对肝脏脂肪成像终点进行暴露-反应建模。
CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):317-330. doi: 10.1002/psp4.13275. Epub 2024 Nov 20.
2
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis.在斑块状银屑病患者中采用零膨胀贝塔分布分析 TYK2/JAK1 抑制剂布罗美替尼的暴露-反应关系。
J Pharmacokinet Pharmacodyn. 2024 Jun;51(3):265-277. doi: 10.1007/s10928-024-09901-2. Epub 2024 Mar 3.
3
Moving Beyond Boundaries: Utilization of Longitudinal Exposure-Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm.超越界限:利用有界结局评分的纵向暴露-反应模型为加速药物开发范式中的决策提供信息。
Clin Pharmacokinet. 2024 Mar;63(3):381-394. doi: 10.1007/s40262-024-01347-6. Epub 2024 Feb 15.
4
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.杜氏肌营养不良症北美之星门诊评估疾病进展建模。
CPT Pharmacometrics Syst Pharmacol. 2023 Mar;12(3):375-386. doi: 10.1002/psp4.12921. Epub 2023 Feb 14.
5
A transformation perspective on marginal and conditional models.关于边际模型和条件模型的一种变换视角。
Biostatistics. 2024 Apr 15;25(2):402-428. doi: 10.1093/biostatistics/kxac048.
6
Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.良性前列腺增生症继发下尿路症状症状量表的有界整数建模。
AAPS J. 2021 Feb 25;23(2):33. doi: 10.1208/s12248-021-00568-y.
7
Applying Beta Distribution in Analyzing Bounded Outcome Score Data.应用 Beta 分布分析有界结局评分数据。
AAPS J. 2020 Mar 17;22(3):61. doi: 10.1208/s12248-020-00441-4.
8
On the Comparison of Methods in Analyzing Bounded Outcome Score Data.《有界结局评分数据分析方法比较》
AAPS J. 2019 Aug 26;21(6):102. doi: 10.1208/s12248-019-0370-6.
9
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.将近似连续的临床终点建模为分类变量:在溃疡性结肠炎患者中应用戈利木单抗 Mayo 评分的纵向暴露-反应建模。
J Pharmacokinet Pharmacodyn. 2018 Dec;45(6):803-816. doi: 10.1007/s10928-018-9610-0. Epub 2018 Oct 30.
10
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.联合纵向模型的开发:在接受 sirukumab 治疗的类风湿关节炎患者的 ACR 和 DAS 评分的暴露-反应建模中的应用。
J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):679-691. doi: 10.1007/s10928-018-9598-5. Epub 2018 Jun 30.